Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Single Domain Antibody-Mediated Blockade of Programmed Death-Ligand 1 on Dendritic Cells Enhances CD8 T-cell Activation and Cytokine Production.

Broos K, Lecocq Q, Keersmaecker B, Raes G, Corthals J, Lion E, Thielemans K, Devoogdt N, Keyaerts M, Breckpot K.

Vaccines (Basel). 2019 Aug 7;7(3). pii: E85. doi: 10.3390/vaccines7030085.

2.

Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent.

Broos K, Lecocq Q, Xavier C, Bridoux J, Nguyen TT, Corthals J, Schoonooghe S, Lion E, Raes G, Keyaerts M, Devoogdt N, Breckpot K.

Cancers (Basel). 2019 Jun 21;11(6). pii: E872. doi: 10.3390/cancers11060872.

3.

Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation.

Fostier K, Caers J, Meuleman N, Broos K, Corthals J, Thielemans K, Schots R, De Keersmaecker B.

Oncotarget. 2018 Apr 17;9(29):20476-20489. doi: 10.18632/oncotarget.24944. eCollection 2018 Apr 17.

4.

mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L, and CD70).

Coosemans A, Tuyaerts S, Morias K, Corthals J, Heirman C, Thielemans K, Van Gool SW, Vergote I, Amant F.

Methods Mol Biol. 2016;1428:277-83. doi: 10.1007/978-1-4939-3625-0_18.

PMID:
27236806
5.

Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma.

Wilgenhof S, Corthals J, Heirman C, van Baren N, Lucas S, Kvistborg P, Thielemans K, Neyns B.

J Clin Oncol. 2016 Apr 20;34(12):1330-8. doi: 10.1200/JCO.2015.63.4121. Epub 2016 Feb 29.

PMID:
26926680
6.

Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases.

Wilgenhof S, Corthals J, Van Nuffel AM, Benteyn D, Heirman C, Bonehill A, Thielemans K, Neyns B.

Cancer Immunol Immunother. 2015 Mar;64(3):381-8. doi: 10.1007/s00262-014-1642-8. Epub 2014 Dec 30.

PMID:
25548092
7.

AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells.

Maenhout SK, Du Four S, Corthals J, Neyns B, Thielemans K, Aerts JL.

Oncotarget. 2014 Aug 30;5(16):6801-15.

8.

Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation.

De Keersmaecker B, Fostier K, Corthals J, Wilgenhof S, Heirman C, Aerts JL, Thielemans K, Schots R.

Cancer Immunol Immunother. 2014 Oct;63(10):1023-36. doi: 10.1007/s00262-014-1571-6. Epub 2014 Jun 20.

PMID:
24947180
9.

Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula.

Van Lint S, Wilgenhof S, Heirman C, Corthals J, Breckpot K, Bonehill A, Neyns B, Thielemans K.

Cancer Immunol Immunother. 2014 Sep;63(9):959-67. doi: 10.1007/s00262-014-1558-3. Epub 2014 May 31. Review.

PMID:
24878889
10.

Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells.

Pen JJ, Keersmaecker BD, Heirman C, Corthals J, Liechtenstein T, Escors D, Thielemans K, Breckpot K.

Gene Ther. 2014 Mar;21(3):262-71. doi: 10.1038/gt.2013.80. Epub 2014 Jan 9.

PMID:
24401835
11.

Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo.

Benteyn D, Anguille S, Van Lint S, Heirman C, Van Nuffel AM, Corthals J, Ochsenreither S, Waelput W, Van Beneden K, Breckpot K, Van Tendeloo V, Thielemans K, Bonehill A.

Mol Ther Nucleic Acids. 2013 Nov 19;2:e134. doi: 10.1038/mtna.2013.54.

12.

A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients.

Wilgenhof S, Van Nuffel AM, Benteyn D, Corthals J, Aerts C, Heirman C, Van Riet I, Bonehill A, Thielemans K, Neyns B.

Ann Oncol. 2013 Oct;24(10):2686-93. doi: 10.1093/annonc/mdt245. Epub 2013 Jul 31.

13.

Modulation of regulatory T cell function by monocyte-derived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4, and CD70.

Pen JJ, De Keersmaecker B, Maenhout SK, Van Nuffel AM, Heirman C, Corthals J, Escors D, Bonehill A, Thielemans K, Breckpot K, Aerts JL.

J Immunol. 2013 Aug 15;191(4):1976-83. doi: 10.4049/jimmunol.1201008. Epub 2013 Jul 10.

14.

Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL).

Benteyn D, Van Nuffel AM, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A.

Biomed Res Int. 2013;2013:976383. doi: 10.1155/2013/976383. Epub 2013 Jan 3.

15.

Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients.

Van Nuffel AM, Benteyn D, Wilgenhof S, Pierret L, Corthals J, Heirman C, van der Bruggen P, Coulie PG, Neyns B, Thielemans K, Bonehill A.

Mol Ther. 2012 May;20(5):1063-74. doi: 10.1038/mt.2012.11. Epub 2012 Feb 28.

16.

Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens.

Van Nuffel AM, Tuyaerts S, Benteyn D, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A.

J Immunol Methods. 2012 Mar 30;377(1-2):23-36. doi: 10.1016/j.jim.2011.12.010. Epub 2012 Jan 16.

PMID:
22269772
17.

A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption.

Allard SD, De Keersmaecker B, de Goede AL, Verschuren EJ, Koetsveld J, Reedijk ML, Wylock C, De Bel AV, Vandeloo J, Pistoor F, Heirman C, Beyer WE, Eilers PH, Corthals J, Padmos I, Thielemans K, Osterhaus AD, Lacor P, van der Ende ME, Aerts JL, van Baalen CA, Gruters RA.

Clin Immunol. 2012 Mar;142(3):252-68. doi: 10.1016/j.clim.2011.10.010. Epub 2011 Nov 16.

PMID:
22177848
18.

Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient.

Van Nuffel AM, Benteyn D, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A.

Cancer Immunol Immunother. 2012 Jul;61(7):1033-43. doi: 10.1007/s00262-011-1176-2. Epub 2011 Dec 10.

PMID:
22159452
19.

Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.

Wilgenhof S, Van Nuffel AM, Corthals J, Heirman C, Tuyaerts S, Benteyn D, De Coninck A, Van Riet I, Verfaillie G, Vandeloo J, Bonehill A, Thielemans K, Neyns B.

J Immunother. 2011 Jun;34(5):448-56. doi: 10.1097/CJI.0b013e31821dcb31.

PMID:
21577140
20.

The combination of 4-1BBL and CD40L strongly enhances the capacity of dendritic cells to stimulate HIV-specific T cell responses.

De Keersmaecker B, Heirman C, Corthals J, Empsen C, van Grunsven LA, Allard SD, Pen J, Lacor P, Thielemans K, Aerts JL.

J Leukoc Biol. 2011 Jun;89(6):989-99. doi: 10.1189/jlb.0810466. Epub 2011 Mar 22.

PMID:
21427207
21.

Restoration of tumor equilibrium after immunotherapy for advanced melanoma: three illustrative cases.

Wilgenhof S, Pierret L, Corthals J, Van Nuffel AM, Heirman C, Roelandt T, De Coninck A, Verfaillie G, Vandenbroucke F, Van Riet I, Bonehill A, Thielemans K, Neyns B.

Melanoma Res. 2011 Apr;21(2):152-9. doi: 10.1097/CMR.0b013e328343ece0.

PMID:
21317818
22.

Immunotherapy of cancer with dendritic cells loaded with tumor antigens and activated through mRNA electroporation.

Van Nuffel AM, Corthals J, Neyns B, Heirman C, Thielemans K, Bonehill A.

Methods Mol Biol. 2010;629:405-52. doi: 10.1007/978-1-60761-657-3_27.

PMID:
20387165
23.

Lumenal part of the DC-LAMP protein is not required for induction of antigen-specific T cell responses by means of antigen-DC-LAMP messenger RNA-electroporated dendritic cells.

De Keersmaecker B, Heirman C, Allard S, Bonehill A, Corthals J, Thielemans K, Aerts JL.

Hum Gene Ther. 2010 Apr;21(4):479-85. doi: 10.1089/hum.2009.080.

PMID:
19903083
24.

Hemorrhagic regression of melanoma metastases during therapeutic vaccination: a report of three cases.

Pierret L, Baren NV, Bonehill A, Corthals J, Van Nuffel AM, Heirman C, Roelandt T, De Coninck A, Riet IV, Degreef E, Goossens A, Verfaillie G, Roseeuw D, Thielemans K, Neyns B.

Melanoma Res. 2009 Dec;19(6):385-90. doi: 10.1097/CMR.0b013e32832eabb5.

PMID:
19707165
25.

Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.

Bonehill A, Van Nuffel AM, Corthals J, Tuyaerts S, Heirman C, François V, Colau D, van der Bruggen P, Neyns B, Thielemans K.

Clin Cancer Res. 2009 May 15;15(10):3366-75. doi: 10.1158/1078-0432.CCR-08-2982. Epub 2009 May 5.

26.

Delivery of tumor-antigen-encoding mRNA into dendritic cells for vaccination.

Michiels A, Tuyaerts S, Bonehill A, Heirman C, Corthals J, Thielemans K.

Methods Mol Biol. 2008;423:155-63. doi: 10.1007/978-1-59745-194-9_10.

PMID:
18370196
27.

Current approaches in dendritic cell generation and future implications for cancer immunotherapy.

Tuyaerts S, Aerts JL, Corthals J, Neyns B, Heirman C, Breckpot K, Thielemans K, Bonehill A.

Cancer Immunol Immunother. 2007 Oct;56(10):1513-37. Epub 2007 May 15. Review.

PMID:
17503040
28.

Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells.

Tuyaerts S, Van Meirvenne S, Bonehill A, Heirman C, Corthals J, Waldmann H, Breckpot K, Thielemans K, Aerts JL.

J Leukoc Biol. 2007 Jul;82(1):93-105. Epub 2007 Apr 20.

PMID:
17449724
29.

CD83 expression on dendritic cells and T cells: correlation with effective immune responses.

Aerts-Toegaert C, Heirman C, Tuyaerts S, Corthals J, Aerts JL, Bonehill A, Thielemans K, Breckpot K.

Eur J Immunol. 2007 Mar;37(3):686-95.

30.

Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA.

Michiels A, Breckpot K, Corthals J, Tuyaerts S, Bonehill A, Heirman C, Thielemans K, Aerts JL.

Gene Ther. 2006 Jul;13(13):1027-36. Epub 2006 Mar 2.

PMID:
16511519
31.

Dendritic cells differentiated in the presence of IFN-{beta} and IL-3 are potent inducers of an antigen-specific CD8+ T cell response.

Breckpot K, Corthals J, Bonehill A, Michiels A, Tuyaerts S, Aerts C, Heirman C, Thielemans K.

J Leukoc Biol. 2005 Oct;78(4):898-908. Epub 2005 Jul 21.

PMID:
16037410
32.

Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines.

Michiels A, Tuyaerts S, Bonehill A, Corthals J, Breckpot K, Heirman C, Van Meirvenne S, Dullaers M, Allard S, Brasseur F, van der Bruggen P, Thielemans K.

Gene Ther. 2005 May;12(9):772-82.

PMID:
15750615
33.

Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein.

Zhang Y, Sun Z, Nicolay H, Meyer RG, Renkvist N, Stroobant V, Corthals J, Carrasco J, Eggermont AM, Marchand M, Thielemans K, Wölfel T, Boon T, van der Bruggen P.

J Immunol. 2005 Feb 15;174(4):2404-11.

34.

Activation of monocytes via the CD14 receptor leads to the enhanced lentiviral transduction of immature dendritic cells.

Breckpot K, Corthals J, Heirman C, Bonehill A, Michiels A, Tuyaerts S, De Greef C, Thielemans K.

Hum Gene Ther. 2004 Jun;15(6):562-73.

PMID:
15212715
35.

Induction of Influenza Matrix Protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells.

Tuyaerts S, Michiels A, Corthals J, Bonehill A, Heirman C, de Greef C, Noppe SM, Thielemans K.

Cancer Gene Ther. 2003 Sep;10(9):696-706.

PMID:
12944989
36.

A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein.

Zhang Y, Chaux P, Stroobant V, Eggermont AM, Corthals J, Maillère B, Thielemans K, Marchand M, Boon T, Van Der Bruggen P.

J Immunol. 2003 Jul 1;171(1):219-25.

37.

A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18.

Bilsborough J, Panichelli C, Duffour MT, Warnier G, Lurquin C, Schultz ES, Thielemans K, Corthals J, Boon T, van der Bruggen P.

Tissue Antigens. 2002 Jul;60(1):16-24.

PMID:
12366779
38.

Generation of large numbers of dendritic cells in a closed system using Cell Factories.

Tuyaerts S, Noppe SM, Corthals J, Breckpot K, Heirman C, De Greef C, Van Riet I, Thielemans K.

J Immunol Methods. 2002 Jun 1;264(1-2):135-51.

PMID:
12191517
39.

A MAGE-1 peptide recognized on HLA-DR15 by CD4(+) T cells.

Chaux P, Lethé B, Van Snick J, Corthals J, Schultz ES, Cambiaso CL, Boon T, van der Bruggen P.

Eur J Immunol. 2001 Jun;31(6):1910-6.

40.

A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes.

Schultz ES, Lethé B, Cambiaso CL, Van Snick J, Chaux P, Corthals J, Heirman C, Thielemans K, Boon T, van der Bruggen P.

Cancer Res. 2000 Nov 15;60(22):6272-5.

41.

Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) DNA sequences are absent in leukapheresis products and ex vivo expanded CD34+ cells from multiple myeloma patients.

De Greef C, Van De Voorde W, Bakkus M, Corthals J, Heirman C, Schots R, Lacor P, Van Camp B, Van Riet I.

Br J Haematol. 1999 Sep;106(4):1033-6.

PMID:
10520008
42.

Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes.

Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P.

J Exp Med. 1999 Mar 1;189(5):767-78.

43.

Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.

De Veerman M, Heirman C, Van Meirvenne S, Devos S, Corthals J, Moser M, Thielemans K.

J Immunol. 1999 Jan 1;162(1):144-51.

44.

[Indications for intertrochanteric osteotomy in severe arthrosis deformans in view of a follow-up study of 190 patients].

Corthals JA.

Ned Tijdschr Geneeskd. 1968 Feb 17;112(7):349-50. Dutch. No abstract available.

PMID:
5636430

Supplemental Content

Loading ...
Support Center